MA32556B1 - Composition pharmaceutique - Google Patents

Composition pharmaceutique

Info

Publication number
MA32556B1
MA32556B1 MA33607A MA33607A MA32556B1 MA 32556 B1 MA32556 B1 MA 32556B1 MA 33607 A MA33607 A MA 33607A MA 33607 A MA33607 A MA 33607A MA 32556 B1 MA32556 B1 MA 32556B1
Authority
MA
Morocco
Prior art keywords
active ingredient
pharmaceutically active
pharmaceutical composition
stabilized
preparation containing
Prior art date
Application number
MA33607A
Other languages
Arabic (ar)
English (en)
Inventor
Yasuhiro Hiraishi
Muneo Nonomura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41327301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32556(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA32556B1 publication Critical patent/MA32556B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique ou une préparation solide contenant un principe pharmaceutiquement actif stabilisé et un procédé de stabilisation de celle-ci. Selon la présente invention, une composition peut être pharmaceutiquement stabilisée par un contenu de principe pharmaceutiquement actif non peptidique possédant un groupe amino primaire ou secondaire, un excipient et un composé acide. Par ailleurs, une préparation solide contenant un principe pharmaceutiquement actif, un oxyde de titane, un plastifiant et un acide organique à chaîne peut renforcer la stabilité du principe pharmaceutiquement actif pendant une irradiation lumineuse.
MA33607A 2008-07-28 2011-02-11 Composition pharmaceutique MA32556B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008194219 2008-07-28
PCT/JP2009/063708 WO2010013823A2 (fr) 2008-07-28 2009-07-27 Composition pharmaceutique

Publications (1)

Publication Number Publication Date
MA32556B1 true MA32556B1 (fr) 2011-08-01

Family

ID=41327301

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33607A MA32556B1 (fr) 2008-07-28 2011-02-11 Composition pharmaceutique

Country Status (29)

Country Link
US (2) US9186411B2 (fr)
EP (2) EP2309985B1 (fr)
JP (2) JP5295356B2 (fr)
KR (1) KR20110042334A (fr)
CN (3) CN102743330B (fr)
AR (1) AR072842A1 (fr)
AU (1) AU2009277443A1 (fr)
BR (1) BRPI0916689A2 (fr)
CA (2) CA2936400C (fr)
CL (1) CL2011000170A1 (fr)
CO (1) CO6290638A2 (fr)
CR (1) CR20110110A (fr)
DO (2) DOP2011000033A (fr)
EA (2) EA201201451A1 (fr)
EC (1) ECSP11010855A (fr)
ES (2) ES2660962T3 (fr)
GE (2) GEP20146166B (fr)
IL (2) IL210735A0 (fr)
MA (1) MA32556B1 (fr)
MX (1) MX2011000757A (fr)
MY (2) MY156305A (fr)
NZ (2) NZ602592A (fr)
PE (3) PE20110591A1 (fr)
SG (1) SG186685A1 (fr)
TW (2) TW201010992A (fr)
UA (1) UA103332C2 (fr)
UY (1) UY32008A (fr)
WO (1) WO2010013823A2 (fr)
ZA (1) ZA201101198B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013122260A1 (fr) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Comprimé
AR091567A1 (es) 2012-06-27 2015-02-11 Takeda Pharmaceutical Preparacion liquida, metodo, kit de inyeccion
MY183976A (en) 2012-09-19 2021-03-17 Taiho Pharmaceutical Co Ltd Pharmaceutical composition for oral administration with improved dissolution and/or absorption
EP3632482A1 (fr) * 2013-03-14 2020-04-08 Allergan, Inc. Système en polymère pour fixer des implants dans des aiguilles de seringue
CN105330647A (zh) * 2014-08-14 2016-02-17 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
CN105985278A (zh) * 2015-01-27 2016-10-05 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
MA41850A (fr) 2015-03-31 2018-02-06 Takeda Pharmaceuticals Co Nouvelles utilisations pharmaceutiques
CN108135915B (zh) 2015-07-30 2021-06-25 武田药品工业株式会社 片剂
CN105106203B (zh) * 2015-08-17 2019-04-05 江苏豪森药业集团有限公司 富马酸沃诺拉赞的药物组合物及其制备方法
CN105030725B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶组合物及其制备方法
CN105030720B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶片及其制备方法
CN107224438B (zh) * 2016-03-25 2021-04-06 江苏豪森药业集团有限公司 富马酸沃诺拉赞药物组合物
US11331316B2 (en) * 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
CN106580903B (zh) * 2016-11-17 2019-12-13 江苏豪森药业集团有限公司 罗红霉素缓释药物组合物
CN106860852A (zh) * 2017-02-17 2017-06-20 王清华 一种用于结合治疗胃病的粘液西药
KR20200013714A (ko) 2017-05-31 2020-02-07 베링거 인겔하임 인터내셔날 게엠베하 (e)-4-(2-(아미노메틸)-3-플루오로알릴옥시)-n-3급-부틸벤즈아미드를 포함하는 약제학적 조성물 및 약제학적 투여 형태, 이들의 제조 방법, 이의 치료 방법 및 용도
BR112020000318A2 (pt) 2017-07-10 2020-07-14 Takeda Pharmaceutical Company Limited preparação
CN108558831B (zh) * 2018-06-08 2021-07-27 上海璃道医药科技有限公司 取代吡咯-4-烷基胺类化合物及其用途
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
CN109288722B (zh) * 2018-11-09 2021-03-30 伯德创研(广州)生物科技有限公司 一种变色修正肤色的粉底及其制备方法
CN110538153B (zh) * 2019-09-26 2022-04-26 扬子江药业集团四川海蓉药业有限公司 一种高稳定性、快速释放的固体制剂及其制备方法
CN115867260B (zh) * 2020-04-24 2024-10-01 福尔克博士药物有限责任公司 用于乳糜泻的吡啶酮衍生物的全身制剂
CN111973565A (zh) * 2020-07-07 2020-11-24 南京海纳医药科技股份有限公司 一种含有富马酸沃诺拉赞的片剂及其溶出度测定方法
CN114053239A (zh) * 2020-08-01 2022-02-18 吉林汇康制药有限公司 一种富马酸伏诺拉生药物组合物及制备方法
CN111943932B (zh) * 2020-08-06 2023-07-14 四川国康药业有限公司 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途
EP4221704B1 (fr) * 2020-10-01 2025-09-24 Imago Biosciences Inc. Formulations pharmaceutiques pour le traitement de maladies médiées par kdm1a
CN114853728B (zh) * 2022-05-07 2023-11-07 四川制药制剂有限公司 一种富马酸伏诺拉生片及其制备方法
CN115364065B (zh) * 2022-08-23 2024-03-15 宁波高新区美诺华医药创新研究院有限公司 富马酸伏诺拉生片
CN115944743B (zh) * 2023-01-18 2025-08-08 山东诚成医药科技有限公司 一种富马酸伏诺拉生组合物及其制备方法
CN116687873A (zh) * 2023-05-26 2023-09-05 四川制药制剂有限公司 一种富马酸伏诺拉生片及其制备方法
WO2025064381A1 (fr) * 2023-09-18 2025-03-27 Phathom Pharmaceuticals Inc. Procédé de préparation de vonoprazan à teneur en nitrosamine réduite
CN119970680B (zh) * 2023-11-10 2025-10-03 中国人民解放军军事科学院军事医学研究院 一种秋水仙碱缓释微丸及其制备方法
CN117462507B (zh) * 2023-12-28 2024-03-15 山东齐都药业有限公司 富马酸伏诺拉生药物组合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2844351B2 (ja) 1989-07-13 1999-01-06 株式会社科薬 安定なポリミキシン系抗生物質水性溶液
US5422362A (en) 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
TW483763B (en) 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
FR2745500B1 (fr) 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
US5834503A (en) 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
FR2752162B1 (fr) 1996-08-07 1998-11-06 Jouveinal Lab Comprime de maleate de trimebutine pellicule
JP4730985B2 (ja) 1997-09-10 2011-07-20 武田薬品工業株式会社 安定化された医薬製剤
EP0901787B1 (fr) 1997-09-10 2003-05-28 Takeda Chemical Industries, Ltd. Composition pharmaceutique stabilisée
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CA2404226A1 (fr) 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Derives de furoisoquinoleine, leur procede de production et leur utilisation
JPWO2003011296A1 (ja) 2001-07-30 2004-11-18 三菱ウェルファーマ株式会社 アミノベンゼンスルホン酸誘導体を活性成分とする医薬品製剤
KR20050037405A (ko) 2001-10-17 2005-04-21 히사미쯔 제약 주식회사 경피 흡수형 제제
WO2003074076A2 (fr) 2002-02-28 2003-09-12 The Penn State Research Foundation Administration de medicaments perioculaires pour retinopathie diabetique
KR101005716B1 (ko) 2002-03-07 2011-01-05 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 ３－［（２－｛［４－（헥실옥시카보닐아미노－이미노-메틸）－페닐아미노］－메틸｝－１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］ 프로피온산 에틸에스테르의 경구 투여 형태
US6818662B2 (en) 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
DE10233108A1 (de) 2002-07-20 2004-01-29 Krewel Meuselbach Gmbh Retardiertes Schmerzmittel enthaltend Tilidin und ein Lichtschutzmittel
EP1572164A2 (fr) * 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Formes posologiques orales comprenant des agents actifs au plan therapeutique dans des noyaux a liberation lente et des revetements de capsule en gelatine a liberation immediate
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
CA2531564C (fr) 2003-07-18 2016-01-19 Santarus, Inc. Formulations pharmaceutiques utilisees pour inhiber une secretion acide et procede de fabrication associe
DE10337697A1 (de) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
JP2005263788A (ja) 2004-02-17 2005-09-29 Sankyo Co Ltd インドリン化合物を含有する安定化された医薬組成物
WO2005094812A1 (fr) 2004-04-01 2005-10-13 Ajinomoto Co., Inc. Préparation contenant du natéglinide
JP2006001912A (ja) 2004-06-21 2006-01-05 Chugai Pharmaceut Co Ltd タンパク質製剤の安定化方法
WO2006036024A1 (fr) * 2004-09-30 2006-04-06 Takeda Pharmaceutical Company Limited Inhibiteurs de pompe a protons
AU2005291302A1 (en) 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
CN101247801B (zh) * 2005-08-25 2012-08-22 协和发酵生化株式会社 血中酒精浓度上升抑制用组合物
AU2006285641A1 (en) * 2005-08-30 2007-03-08 Takeda Pharmaceutical Company Limited 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
CA2634637A1 (fr) 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited Preparation solide a liberation controlee
CN101516367A (zh) 2006-09-15 2009-08-26 安斯泰来制药有限公司 对光稳定的雷莫司琼的固态医药组合物
JP5074052B2 (ja) 2007-02-13 2012-11-14 有限会社愛和ライト 遊技機
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
WO2009041705A2 (fr) 2007-09-28 2009-04-02 Takeda Pharmaceutical Company Limited Composé hétérocyclique à 5 chaînons
WO2009041447A1 (fr) 2007-09-28 2009-04-02 Takeda Pharmaceutical Company Limited Composé hétérocyclique à 5 chaînons
EP2226075A1 (fr) 2007-11-22 2010-09-08 The University of Tokyo Matériau destiné à la prévention de l'adhérence tissulaire et matériau destiné à la prévention des contractures articulaires

Also Published As

Publication number Publication date
EP2309985A2 (fr) 2011-04-20
EP2564833B1 (fr) 2017-12-20
AU2009277443A1 (en) 2010-02-04
NZ602592A (en) 2014-01-31
EA201201451A1 (ru) 2013-07-30
WO2010013823A2 (fr) 2010-02-04
WO2010013823A3 (fr) 2010-04-15
CL2011000170A1 (es) 2011-06-10
CA2936400C (fr) 2018-03-27
NZ591344A (en) 2013-03-28
DOP2011000033A (es) 2011-04-15
GEP20146122B (en) 2014-07-25
IL210735A0 (en) 2011-03-31
CR20110110A (es) 2011-04-28
CO6290638A2 (es) 2011-06-20
JP2013047239A (ja) 2013-03-07
MY169461A (en) 2019-04-11
EA201170272A1 (ru) 2011-10-31
CN102743330A (zh) 2012-10-24
MX2011000757A (es) 2011-02-24
ZA201101198B (en) 2012-05-30
ES2669592T3 (es) 2018-05-28
PE20141585A1 (es) 2014-11-13
EP2309985B1 (fr) 2018-03-14
US9186411B2 (en) 2015-11-17
TW201010992A (en) 2010-03-16
US20130261156A1 (en) 2013-10-03
PE20110591A1 (es) 2011-09-15
UA103332C2 (ru) 2013-10-10
IL228817A0 (en) 2013-12-31
JP2011529445A (ja) 2011-12-08
CA2732243C (fr) 2016-11-29
AR072842A1 (es) 2010-09-22
KR20110042334A (ko) 2011-04-26
ES2660962T3 (es) 2018-03-26
US20110124687A1 (en) 2011-05-26
CA2732243A1 (fr) 2010-02-04
EP2564833A1 (fr) 2013-03-06
MY156305A (en) 2016-01-29
CN104784180A (zh) 2015-07-22
DOP2013000172A (es) 2013-11-15
CN102164581A (zh) 2011-08-24
ECSP11010855A (es) 2011-03-31
CN102743330B (zh) 2016-03-23
JP5593363B2 (ja) 2014-09-24
SG186685A1 (en) 2013-01-30
CA2936400A1 (fr) 2010-02-04
UY32008A (es) 2010-02-26
GEP20146166B (en) 2014-09-25
BRPI0916689A2 (pt) 2015-11-17
TW201431552A (zh) 2014-08-16
PE20140977A1 (es) 2014-08-20
JP5295356B2 (ja) 2013-09-18

Similar Documents

Publication Publication Date Title
MA32556B1 (fr) Composition pharmaceutique
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
EA201391758A1 (ru) Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты
WO2008021871A3 (fr) Inhibiteurs triazolyle acyclique de la sérine protéase de l'hépatite c
WO2008019266A3 (fr) Inhibiteurs de sérine protéase de l'hépatite c dérivés de pyridazinone acycliques
ECSP045307A (es) Combinacion de compuestos organicos
WO2009053828A3 (fr) Inhibiteurs p3-hydroxyamino macrocycliques des sérine protéases de l'hépatite c
EA201170289A1 (ru) Фармацевтические композиции и способы их получения при низкой концентрации примесей
MA31706B1 (fr) Formulations galéniques de composés organiques
WO2009066041A3 (fr) Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX2010008109A (es) Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).
PH12023552774A1 (en) Nek7 inhibitors
BR112022015925A2 (pt) Combinações de compostos beta-lactâmicos, probenecida e ácido valproico e usos dos mesmos
PL1853292T3 (pl) Kompozycja farmaceutyczna, zawierająca związki glutationu i betalainy, do prewencji i do zwalczania raka
PE20220486A1 (es) Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
MX378113B (es) Composiciones para la prevención y el tratamiento profiláctico de dermatitis por hiedra venenosa.
WO2008057464A3 (fr) Compositions et procédés servant à améliorer la biodisponibilité de la liothyronine
MA29560B1 (fr) Formulation a liberation prolongee de principes actifs de medicaments
WO2010056041A3 (fr) Composition pharmaceutique destinée au traitement et à la prévention d'affections cardiaques résultant d'ischémie ou de reperfusion ischémique
BRPI0507030A (pt) combinação de compostos orgánicos
FR3117337B1 (fr) Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable
MX2022012848A (es) Composicion farmaceutica que comprende compuesto derivado de benzimidazol.
TN2011000030A1 (en) Pharaceutical composition
WO2007047881A3 (fr) Methode de traitement de la douleur